Monoclonal Antibodies for Multiple Sclerosis Treatment

Abstract

RESUMODesde a sua introdução na terapêutica médica, no último quarto do século XX, os anticorpos monoclonais têm ganho cada vez mais importância no tratamento de várias doenças. A Neurologia tem sido uma das especialidades médicas a beneficiar do potencial terapêutico destes anticorpos monoclonais e algumas doenças neurológicas podem já contar com fármacos deste tipo nos seus algoritmos terapêuticos. A esclerose múltipla é uma dessas doenças e, para além dos já licenciados para utilização clínica, são vários os anticorpos monoclonais que se encontram em desenvolvimento para futura utilização nesta área específica. O futuro passará certamente por fármacos deste tipo e, neste artigo, far-se-á uma revisão dos dados mais relevantes relacionados com os anticorpos monoclonais já em uso e também em desenvolvimento clínico para tratamento da esclerose múltipla. Palavras-chave: Anticorpos Monoclonais; Ensaios Clínicos; Esclerose Múltipla. ABSTRACTSince their introduction in medical therapy, in the last quarter of the 20 th century, monoclonal antibodies have gained an increasing importance in the treatment of various diseases. Neurology has been one of the medical specialties benefiting of the therapeutic potential of these monoclonal antibodies and certain neurological conditions may now contain such drugs in their therapeutic algorithms. Multiple sclerosis is one of these diseases and, in addition to the monoclonal antibodies already licensed for clinical use, several others are in development for future utilization in this specific area. The future will certainly pass through this kind of drugs and, in this article, a review of the most relevant data related to monoclonal antibodies already in use and also in clinical development for multiple sclerosis treatment will be performed.

Mapping the Therapeutic Options for Multiple Sclerosis in Brazil: A Comprehensive Analysis

“…However, it is important to mention that indications and approvals granted by regulatory agencies vary between countries. Notably, in Europe, these agents have not yet been licensed for the treatment of less active forms of the disease, based on a weighted analysis of benefits versus risks [30][31][32][33]. Figure 1 shows the drug, along with its main mechanisms of action and the year of approval of the drug by ANVISA.…”

Update on Disease-Modifying Therapies for Multiple Sclerosis

“…Currently, there are three agents that target the CD20 cell surface marker on B cells that are under study. These are rituximab, ocrelizumab and ofatumumab 31 33 98…”